Pdp (68071 3453 2)
Amlodipine Besylate Tablet
Product Images NDC 68071-3453
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Amlodipine Besylate (NDC 68071-3453). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure-1 (Figure1)
Figure-2 (Figure2)
Overall, there were 1318 patients involved in this evaluation. They were divided into two age groups: <65 years old (N=085) and >= 65 years old (N=333). The gender distribution was 984 males and 334 females. The baseline sitting systolic blood pressure (SBP) was categorized as <= mean (N=699) and > mean (N=618). Under baseline vessel disease, there were no occurrences of single vessel disease, but there were 1315 cases of multiple vessel disease. In terms of baseline vessels with stenosis, 850 patients had at least one vessel with more than 60% stenosis, while 465 patients did not have any vessels with more than 60% stenosis. The strata for PCl-stent included 680 patients with no percutaneous coronary intervention (PCI), 53 patients with PCI but without stent placement, and 585 patients with stent placement. The comparison between amlodipine and placebo did not favor either treatment. The mean sitting baseline SBP was 129 mmHg. The hazard ratio (with a 95% confidence interval) is not available.*
Structure (Structure)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
